Physician profile
Joseph E Martin
NPI 1912983859
$3,504.76
in general payments reported to CMS, 2019-2025
33 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $365 · 2021: $266 · 2022: $449 · 2023: $537 · 2024: $738 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,093.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $956.74 | 2019-2025 | |
| Novo Nordisk INC | $287.29 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $286.04 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $271.68 | 2024-2025 | Fanapt, Hetlioz |
| Amgen INC. | $191.75 | 2019-2025 | Otezla, Repatha, Evenity |
| Allergan, INC. | $186.08 | 2019-2020 | |
| Lilly USA, LLC | $185.02 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $148.45 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $135.40 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.74 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $96.63 | 2022-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $83.56 | 2024-2025 | Ingrezza |
| Glaxosmithkline, LLC. | $67.69 | 2020-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.71 | 2019-2024 | Tradjenta, Jardiance |
| Astrazeneca Pharmaceuticals LP | $41.82 | 2019-2025 | Breztri |
Show all 33 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.